NLS Pharma
Financials
Estimates*
USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
EBITDA | (4.3m) | (2.6m) | (11.9m) | (15.5m) | (12.0m) | - | - |
Profit | (5.4m) | (2.9m) | (11.9m) | (16.5m) | (12.2m) | (2.2m) | (26.7m) |
EV / EBITDA | - | - | -1.4x | -2.8x | -0.7x | - | - |
R&D budget | 1.7m | <1m | 5.9m | 9.0m | 5.9m | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
* | N/A | N/A | Series B |
N/A | N/A | IPO | |
* | N/A | $4.0m | Private Placement VC |
* | $10.0m | Private Placement VC | |
* | N/A | $1.8m | Post IPO Equity |
* | N/A | Acquisition | |
Total Funding | €12.7m |
Recent News about NLS Pharma
EditNLS Pharmaceutics is a biopharmaceutical company focused on designing affordable, safe, and effective drugs to safeguard and empower the brain throughout all stages of life. The company aims to improve quality of life and longevity by creating new approaches to treat mental and behavioral disorders, as well as enhancing cognitive function in healthy individuals. NLS Pharmaceutics operates in the healthcare and pharmaceutical market, serving patients with mental health needs and cognitive enhancement desires. The business model revolves around research and development of novel therapeutics, which are then brought to market through clinical trials and regulatory approvals. Revenue is generated through the sale of these drugs, partnerships, and licensing agreements.
Keywords: biopharmaceutical, mental health, cognitive enhancement, drug development, affordable therapeutics, brain health, clinical trials, regulatory approvals, healthcare, pharmaceutical.